or Try an Advanced Search...

    Technical Analysis for CRDL - Cardiol Therapeutics Inc

    Grade Last Price % Change Price Change
    C 3.130 0.97% 0.030
    CRDL closed up 0.97 percent on Friday, July 26, 2024, on 48 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
    Earnings due: Aug 8
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical CRDL trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    NR7 Range Contraction 0.00%
    Overbought Stochastic Strength 0.00%
    Stochastic Sell Signal Bearish 0.97%
    Crossed Above 50 DMA Bullish 0.97%
    Spinning Top Other 0.97%
    Upper Bollinger Band Walk Strength 0.97%
    Overbought Stochastic Strength 0.97%
    Fell Below 50 DMA Bearish 2.96%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.96%
    Older End-of-Day Signals for CRDL ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    50 DMA Support about 7 hours ago
    Down 1% about 7 hours ago
    Fell Below 50 DMA about 7 hours ago
    Upper Bollinger Band Resistance about 8 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CRDL Chart by TradingView
    Basic chart:

    Profile

    Cardiol Therapeutics Inc Description

    Cardiol Therapeutics Inc is a Canada-based company engaged in the pharmaceutical business sector. The Company is focused on the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. It has research programs focused on development of nanotherapeutics to treat heart failure underway. The Company invests in development of formulations for three medical markets: commercializing a line of purity pharmaceutically-manufactured cannabidiol products in the market for medical cannabinoids; development of nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure, a cause of death and hospitalization, and pursuing an immunotherapeutics program commencing with a cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharma Pharmaceutical Drug Cancer Drugs Heart Organ Systems Cannabinoid Blastoma Cannabidiol Cannabinoids Glioblastoma Pharmaceutical Business Sector

    Is CRDL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 12 We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
    Jun 27 Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
    Jun 25 Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
    Jun 17 Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
    Jun 13 Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
    May 14 Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
    Apr 2 Cardiol Therapeutics Announces Year-End 2023 Update on Operations
    Feb 21 Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
    Feb 15 Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
    Jan 24 Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
    See more CRDL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.26
    52 Week Low 0.91
    Average Volume 179,551
    200-Day Moving Average 2.081
    50-Day Moving Average 3.065
    20-Day Moving Average 2.856
    10-Day Moving Average 2.997
    Average True Range 0.211
    RSI (14) 55.75
    ADX 15.95
    +DI 25.227
    -DI 15.145
    Chandelier Exit (Long, 3 ATRs) 2.628
    Chandelier Exit (Short, 3 ATRs) 3.142
    Upper Bollinger Bands 3.231
    Lower Bollinger Band 2.481
    Percent B (%b) 0.87
    BandWidth 26.275
    MACD Line 0.042
    MACD Signal Line -0.009
    MACD Histogram 0.0504
    Fundamentals Value
    Market Cap 102.7 Million
    Num Shares 32.8 Million
    EPS -1.02
    Price-to-Earnings (P/E) Ratio -3.07
    Price-to-Sales 0.00
    Price-to-Book 3.94
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.370
    Resistance 3 (R3) 3.367 3.283 3.330
    Resistance 2 (R2) 3.283 3.222 3.285 3.317
    Resistance 1 (R1) 3.207 3.184 3.245 3.210 3.303
    Pivot Point 3.123 3.123 3.143 3.125 3.123
    Support 1 (S1) 3.047 3.062 3.085 3.050 2.957
    Support 2 (S2) 2.963 3.024 2.965 2.943
    Support 3 (S3) 2.887 2.963 2.930
    Support 4 (S4) 2.890